Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) Files An 8-K Other EventsItem 8.01 Other Events.
Alder BioPharmaceuticals, Inc. (“Alder”) is filing this Current Report on Form 8-K to provide a copy of the legal opinion of Cooley LLP relating to the legality of Alder’s common stock, par value $0.0001 per share, to be offered and sold to Alder’s Registration Statement on Form S-3 (File No.333-216199) and the related prospectus supplement, dated February9, 2018, and filed with the U.S. Securities and Exchange Commission to Rule 424 under the Securities Act.
In addition, Alder has updated certain risk factors it previously disclosed in its current and periodic reports as filed with the Securities and Exchange Commission from time to time. A copy of the updated risk factors is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated by reference herein.
Forward LookingStatements
This Current Report on Form8-Kcontainsforward-lookingstatements, including, without limitation, statements relating to: the continued development and clinical, therapeutic and commercial potential of eptinezumab; the availability of clinical trial data; and future regulatory submissions. Words such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “potential” and similar expressions identifyforward-lookingstatements, but the absence of these words or expressions does not necessarily mean that a statement is notforward-looking. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances areforward-lookingstatements. Theforward-lookingstatements in this Current Report on Form8-Kare based upon our current plans, assumptions, beliefs, expectations, estimates and projections, and involve substantial risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in theforward-looking statements due to these risks and uncertainties as well as other factors, which include, without limitation: risks related to the potential failure of eptinezumab to demonstrate safety and efficacy in clinical testing; the availability of data at the expected times; the clinical, therapeutic and commercial value of eptinezumab; risks and uncertainties related to regulatory review and approval processes and our compliance with applicable legal and regulatory requirements; the uncertain timing and level of expenses associated with the development of eptinezumab; the sufficiency of our capital and other resources; market competition; changes in economic and business conditions; and other factors discussed in the revised risk factors is attached to this Current Report on Form 8-K, and our other filings with the Securities and Exchange Commission. Theforward-lookingstatements made in this Current Report on Form8-Kspeak only as of the date of this Current Report on Form8-K.We expressly disclaims any duty, obligation or undertaking to release publicly any updates or revisions to anyforward-lookingstatements contained herein to reflect any change in the our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Item 8.01 Financial Statements and Exhibits.
(d) Exhibits.
ALDER BIOPHARMACEUTICALS INC ExhibitEX-5.1 2 d479245dex51.htm EX-5.1 EX-5.1 Exhibit 5.1 February 9,…To view the full exhibit click here
About Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR)
Alder Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and focuses to commercialize therapeutic antibodies with the potential to transform current treatment paradigms. The Company’s pipeline includes ALD403, Clazakizumab and ALD1613. ALD403 is the Company’s monoclonal antibody targeted to calcitonin gene-related peptide (CGRP) for migraine prevention. Clazakizumab is a monoclonal antibody that inhibits the pro-inflammatory cytokine interleukin-6 (IL-6), and is in development for both rheumatoid arthritis (RA) and psoriatic arthritis (PsA). ALD1613 is a monoclonal antibody that inhibits Adrenocorticotropic Hormone, and is being developed for the treatment of Cushing’s disease. Its candidate, Eptinezumab, is an investigational product candidate being developed as a migraine prevention treatment for patients with chronic and frequent episodic migraine. It is also is developing ALD1910, a genetically engineered monoclonal antibody.
